Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

16 evidence topics · 13 sources

Summary

Lanifibranor is an investigational medicine that has not been approved by any regulatory authority. It is being evaluated in the phase 3 NATiV3 trial in patients with MASH with moderate and advanced fibrosis, and the manufacturer expects to report topline results in the fourth quarter of 2026. In the EASL guideline, management of MASLD consists of lifestyle modification and optimal management of comorbidities, including incretin-based therapies for type 2 diabetes or obesity, with resmetirom, if approved locally, considered as a MASH-targeted therapy for non-cirrhotic MASH with fibrosis stage 2 or higher; no MASH-targeted pharmacotherapy is recommended for the cirrhotic stage. The same guideline describes a phase IIb trial of lanifibranor with dose-dependent histological improvement of steatohepatitis and fibrosis and side effects of a 2.5% increase in weight, pedal oedema, and mild anaemia. For adults with type 2 diabetes and biopsy-proven MASH or high risk of liver fibrosis, the American Diabetes Association prefers a GLP-1 RA for glycemic management, allows pioglitazone plus a GLP-1 RA, and advises referral to a gastroenterologist or hepatologist for consideration of a thyroid hormone receptor-β agonist.

The American Diabetes Association states that MASH therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team, and the Cigna prior authorization policy for Rezdiffra requires prescribing by or in consultation with an endocrinologist, gastroenterologist, or hepatologist. About 14% of MAESTRO-NASH participants were receiving a GLP-1 RA, and the EASL guideline considers it reasonable to use resmetirom by the same criteria in these individuals; the AASLD resmetirom update states that data are insufficient to guide whether or when to start resmetirom in persons already taking therapies with potential MASH efficacy. Combination use of semaglutide 2.4 mg/week with resmetirom has not been studied, and another publication did not recommend upfront combination therapy and supported treatment consideration with resmetirom or semaglutide for noncirrhotic MASLD with liver stiffness of 10 to 20 kPa or ELF of 9.2 to 11.3. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription, mostly before resmetirom (33.8%), and 231 of the remaining 4524 (5.1%) were co-initiators.

The manufacturer describes lanifibranor as a once-daily oral therapy, plans to demonstrate its value as monotherapy and in combination, and states that NATiV3 assesses lanifibranor in combination with GLP-1 and SGLT2 inhibitors. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.